Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Lockdown

- PMLiVE

Moderna’s JN.1-adapted COVID-19 vaccine approved by MHRA for adults and children

The JCVI has already advised the UK government on eligible groups for this year’s autumn vaccination programme

- PMLiVE

Novavax’s JN.1-adapted COVID-19 vaccine granted FDA emergency use authorisation

JN.1 only accounts for 0.2% of cases across the country but is the ‘parent strain’ of currently circulating variants

- PMLiVE

FDA approves updated COVID-19 vaccines to better protect against current variants

Adapted vaccines from Pfizer/BioNTech and Moderna have been authorised for individuals aged six months and older

- PMLiVE

JCVI announces advice for autumn COVID-19 vaccination programme eligibility

The Committee has advised offering the vaccine to those at high risk of serious disease

- PMLiVE

AstraZeneca’s sipavibart shown to prevent COVID-19 in immunocompromised patients

Immunocompromised individuals account for about 25% of COVID-19 hospitalisations, intensive care unit admissions and deaths

- PMLiVE

Study reveals third COVID-19 vaccine dose improves defence in vulnerable patients

Approximately 90% of patients who received a third dose developed significant levels of antibodies

- PMLiVE

Sanofi and Novavax announce COVID-19 vaccine licensing agreement worth over $1.2bn

The deal gives Sanofi a licence to use Novavax’s COVID-19 vaccine in combination with its own flu vaccines

- PMLiVE

Researchers’ new vaccine technology shows efficacy against broad range of coronaviruses

The vaccine provided protection against coronaviruses that have not yet emerged

- PMLiVE

AstraZeneca begins global withdrawal of COVID-19 vaccine following decline in demand

The company applied to voluntarily withdraw its European marketing authorisation on 5 March

- PMLiVE

WHO reveals ‘extensive’ worldwide overuse of antibiotics during COVID-19 pandemic

Findings from the report reveal factors that could have contributed to the spread of antimicrobial resistance

- PMLiVE

Gilead’s Veklury receives NICE recommendation to treat COVID-19 in vulnerable adults and children

Veklury is now the first antiviral recommended by the agency to treat eligible children

- PMLiVE

FDA grants Invivyd’s Pemgarda emergency use authorisation for COVID-19 prevention

The long-acting monoclonal antibody is authorised for use in adults and adolescents

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links